← Back to Home

Full SAFFRON data released: Dual targeted therapy extends median survival by 4.9 months over chemotherapy in a specific drug-resistant lung cancer population

Following the announcement that the trial met its endpoint, the disclosure of the magnitude of benefit adds survival evidence for savolitinib plus osimertinib in drug-resistant lung cancer with high MET expression or amplification. However, the dual oral regimen still carries a substantial treatment burden, with a rate of grade 3 or higher adverse events similar to chemotherapy.

By SURL BioNews

When lung cancer progresses again after targeted therapy, can identifying the resistance mechanism point to a next step? Detailed results from the Phase 3 SAFFRON trial provide a more concrete answer: among patients whose disease progressed after osimertinib treatment and whose tumors had specific MET abnormalities, adding savolitinib resulted in a median overall survival of 17.8 months, compared with 12.9 months in the platinum-based chemotherapy group—a difference of 4.9 months.

The newly released findings supplement the earlier announcement that the trial had met its endpoint with the magnitude of efficacy, patient selection criteria, and safety data needed to assess the results. The study was presented at a Presidential Symposium at the European Society for Medical Oncology Congress on October 25, 2026, and published in The New England Journal of Medicine the same day. Institut Curie in France, which participated in the study, also confirmed the survival benefit. The international randomized trial enrolled 338 patients: 171 received savolitinib plus osimertinib, and 167 received chemotherapy with a platinum agent and pemetrexed.

The hazard ratio for death in the overall survival analysis was 0.68, with a 95% confidence interval of 0.50 to 0.91, corresponding to a 32% reduction in the relative risk of death during follow-up. This does not mean that every patient would live longer by the same amount. Median progression-free survival, the trial’s primary endpoint assessed by blinded independent central review, increased from 5.4 months in the chemotherapy group to 7.6 months in the combination group; the hazard ratio for disease progression or death was 0.55.

The limits of applicability of the benefit lie in the enrollment criteria. Patients had to have EGFR-mutated, locally advanced or metastatic non-small cell lung cancer that progressed during osimertinib treatment, and also meet strict MET thresholds: at least 90% of tumor cells showing 3+ staining intensity on immunohistochemistry; or at least 10 MET gene copies detected by fluorescence in situ hybridization; or both. The results therefore cannot be directly generalized to all patients who develop resistance after EGFR-targeted therapy.

Oral administration does not mean mild side effects. The most common adverse events in the combination group included peripheral edema (49%), anemia (26%), and diarrhea (26%); grade 3 or higher adverse events during treatment occurred in 64%, compared with 63% in the chemotherapy group. Although Institut Curie’s press release broadly described side effects as being halved, the overall rates of grade 3 or higher events reported in the journal abstract do not support that interpretation and cannot be used to claim that the dual targeted regimen has lower overall toxicity.

Background

Osimertinib controls tumors by inhibiting EGFR signaling, but some cancer cells maintain growth through MET signaling, creating another pathway of resistance. Savolitinib inhibits MET, and pairing it with osimertinib, which continues to inhibit EGFR, aims to block both the original driver signal and the newly emerging escape pathway. The value of SAFFRON lies in using a randomized Phase 3 trial to test whether this strategy of adjusting treatment according to the resistance mechanism can translate into a survival advantage.

The study used an open-label design, meaning that patients and treatment teams knew which therapy was being given; the primary progression-free survival endpoint was assessed by blinded independent review to reduce assessment bias. Funded by AstraZeneca, the trial provides stronger evidence for patients selected through strict biomarker criteria. However, the comparator was limited to platinum plus pemetrexed, so the findings cannot establish superiority over all later-line therapies. The key considerations for clinical application therefore center on accurately identifying MET abnormalities and weighing survival benefit against treatment burden.

References

  1. HUTCHMED via GlobeNewswire
  2. New England Journal of Medicine via PubMed
  3. Institut Curie